|
|
Taiwan Academic Institutional Repository >
Browse by Title
|
Showing items 707776-707800 of 2348439 (93938 Page(s) Totally)
<< < 28307 28308 28309 28310 28311 28312 28313 28314 28315 28316 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
| 國立成功大學 |
2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, A.X.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Pracht, M.;Lim, H.Y.;Rau, K.-M.;Motomura, K.;Ohno, I.;Merle, P.;Daniele, B.;Shin, D.B.;Gerken, Gerken G.;Borg, C.;Hiriart, J.-B.;Okusaka, T.;Morimoto, Morimoto M.;Hsu, Y.;Abada, P.B.;Kudo, M.;investigators, REACH-2 study |
| 臺大學術典藏 |
2022-09-15T01:08:52Z |
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
|
Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; Chia-Chi Lin |
| 國立成功大學 |
2022 |
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study: RAM/PL + BSC for advanced HCC
|
Shao, G.;Bai, Y.;Yuan, X.;Chen, X.;Gu, S.;Gu, K.;Hu, C.;Liang, H.;Guo, Y.;Wang, J.;Yen, C.-J.;Lee, V.H.-F.;Wang, C.;Widau, R.C.;Zhang, W.;Liu, J.;Zhang, Q.;Qin, S. |
| 國立成功大學 |
2021 |
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: Pooled results from two phase 3 studies (REACH and REACH-2)
|
Kudo, M.;Finn, R.S.;Morimoto, Morimoto M.;Rau, K.-M.;Ikeda, M.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Daniele, B.;Lim, H.Y.;McIlwain, D.W.;Yoshikawa, R.;Nakamura, K.;Liang, K.;Wang, C.;Abada, P.;Widau, R.C.;Zhu, A.X. |
| 臺大學術典藏 |
2021-05-02T03:49:13Z |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
|
Nishio M.;Seto T.;Reck M.;Garon E.B.;Chiu C.-H.;Yoh K.;Imamura F.;Park K.;Jin-Yuan Shih;Visseren-Grul C.;Frimodt-Moller B.;Zimmermann A.;Homma G.;Enatsu S.;Nakagawa K.;Relay Study Investigators; Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators |
| 臺大學術典藏 |
2021-01-18T09:12:07Z |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
|
Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B.; Chiu, Chao Hua; Yoh, Kiyotaka; Imamura, Fumio; Park, Keunchil; JIN-YUAN SHIH; Visseren-Grul, Carla; Frimodt-Moller, Bente; Zimmermann, Annamaria; Homma, Gosuke; Enatsu, Sotaro; Nakagawa, Kazuhiko |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
|
Aarts M.J.B; Erdkamp F.L.G; Blaisse R.J.B; Flores C.L.U; Cort?s L.V; Lee Y.-G; Kim Y.J; Rha S.Y; Ferrario C; Sengeloev L; Jensen N.V; Thibault C; Laguerre B; Joly F; Flechon A; Culine S; Becht C; Niegisch G; St?ckle M; Grimm M.-O; Gakis G; Schultze-Seemann W; Kalofonos H; Mavroudis D; Papandreou C; Karavasilis V; R?v?sz J; Geczi L; Rosenbaum E; Leibowitz-Amit R; Kejzman D; Sarid D; Scagliotti G.V; Bracarda S; Massari F; Osawa T; Miyajima N; Shinohara N; Fukuta F; Ohyama C; Obara W; Yamashita S; Tomita Y; Kawai K; Fukasawa S; Oyama M; Yonese J; Nagata M; Uemura M; Nishimura K; Kawakita M; Tsunemori H; Hashine K; Inokuchi J; Yokomizo A; Nagamori S; Lee H.J; Park S.H; Alekseev B; Necchi A; G?czi L; Ou Y.-C; Coskun H.S; Su W.-P; Hegemann M; Percent I.J; Lee J.-L; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; del Muro X.G; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau R.C; Liepa A.M; Walgren R.A; Hamid O; Zimmermann A.H; Bell-McGuinn K.M; Powles T; Wong S.-L.S; Tan T.H; Hovey E.J; Clay T.D; Ng S.S.W; Rutten A; Machiels J.-P; Dumez H; Cheng S.Y.-S; Petrylak D.P; de Wit R; Chi K.N; Drakaki A; Sternberg C.N; Nishiyama H; Castellano D; Hussain S; Fl?chon A; Bamias A; Yu E.Y; van der Heijden M.S; Matsubara N; Vaishampayan U.; Aragon-Ching J; Tagawa S; Lawler W; Lowe T; Herms B; Hainsworth J; Cultrera J; Schwarz J; Flaig T; Pan C.X; Wojcik-Tomaszewska J; Tomczak P; Sikora-Kupis B; Schenker M; Herzal A.A; Udrea A.A; Karlov P; Fomkin R; Pulido E.G; Mignorance J.I.D; Gauna D.C; Rodr?guez-Vida A; Su Y.-L; Lin C.-L; Chia-Chi Lin; Yeh S.-P; ?i?in I; Erman M; Urun Y; Golovko Y; Bondarenko I; Sinielnikov I; Crabb S; Syndikus I; Huddart R; Sundar S; Chowdhury S; Sarwar N |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak D.P; de Wit R; Chi K.N; Drakaki A; Sternberg C.N; Nishiyama H; Castellano D; Hussain S.A; Fl?chon A; Bamias A; Yu E.Y; van der Heijden M.S; Matsubara N; Alekseev B; Necchi A; G?czi L; Ou Y.-C; Coskun H.S; Su W.-P; Bedke J; Gakis G; Percent I.J; Lee J.-L; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa S.T; Vaishampayan U; Aragon-Ching J.B; Hamid O; Liepa A.M; Wijayawardana S; Russo F; Walgren R.A; Zimmermann A.H; Hozak R.R; Bell-McGuinn K.M; Powles T; Wong S.-L.S; Tan T.H; Hovey E.J; Clay T.D; Wan Ng S.S; Rutten A; Machiels J.-P; Dumez H; Cheng S.Y.-S; Ferrario C; Sengeloev L; Jensen N.V; Thibault C; Laguerre B; Joly F; Culine S; Becht C; Niegisch G; St?ckle M; Grimm M.-O; Schwentner C.A; Schultze-Seemann W; Kalofonos H; Mavroudis D; Papandreou C; Karavasilis V; R?v?sz J; Rosenbaum E; Leibowitz-Amit R; Kejzman D; Sarid D; Scagliotti G.V; Bracarda S; Massari F; Osawa T; Miyajima N; Shinohara N; Fukuta F; Ohyama C; Obara W; Yamashita S; Tomita Y; Kawai K; Fukasawa S; Oyama M; Yonese J; Nagata M; Uemura M; Nishimura K; Kawakita M; Tsunemori H; Hashine K; Inokuchi J; Yokomizo A; Nagamori S; Lee H.J; Park S.H; Rha S.Y; Kim Y.J; Lee Y.-G; Vazquez Cort?s L; Lorena Urzua Flores C; Blaisse R.J.B; Erdkamp F.L.G; Aarts M.J.B; Wojcik-Tomaszewska J; Tomczak P; Sikora-Kupis B; Schenker M; Herzal A.A; Udrea A.A; Karlov P; Fomkin R; Gajate Borau P; Grande E; Delgado Mignorance J.I; Su Y.-L; Li J.-R; Lin C.-L; Chia-Chi Lin; Yeh S.-P; Erman M; Urun Y; Golovko Y; Bondarenko I; Sinielnikov I; Crabb S.J; Syndikus I; Huddart R; Sundar S; Chowdhury S; Sarwar N; Flaig T.W; Pan C.X; Schwarz J.K; Cultrera J.L; Acs P.I; Hainsworth J.D; Herms B.T; Lawler W.E; Lowe T.E. |
| 臺大學術典藏 |
2022-09-15T01:09:02Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Fl?chon A.; Bamias A.; Yu E.Y.; van der Heijden M.S.; Matsubara N.; Alekseev B.; Necchi A.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.; Lee Y.-G.; Vazquez Cort?s L.; Lorena Urzua Flores C.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Gajate Borau P.; Grande E.; Delgado Mignorance J.I.; Su Y.-L.; Li J.-R.; Lin C.-L.; Chia-Chi Lin; Yeh S.-P.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Sinielnikov I.; Crabb S.J.; Syndikus I.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.W.; Pan C.X.; Schwarz J.K.; Cultrera J.L.; Acs P.I.; Hainsworth J.D.; Herms B.T.; Lawler W.E.; Lowe T.E. |
| 國立成功大學 |
2020 |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak, D.P.;de, Wit R.;Chi, K.N.;Drakaki, A.;Sternberg, C.N.;Nishiyama, H.;Castellano, D.;Hussain, S.A.;Fl�chon, A.;Bamias, A.;Yu, E.Y.;van, der Heijden M.S.;Matsubara, N.;Alekseev, B.;Necchi, A.;G�czi, L.;Ou, Y.-C.;Coskun, H.S.;Su, W.-P.;Bedke, J.;Gakis, Gakis G.;Percent, I.J.;Lee, J.-L.;Tucci, M.;Semenov, A.;Laestadius, F.;Peer, A.;Tortora, G.;Safina, Safina S.;Garcia, del Muro X.;Rodriguez-Vida, A.;Cicin, I.;Harputluoglu, Harputluoglu H.;Tagawa, S.T.;Vaishampayan, U.;Aragon-Ching, J.B.;Hamid, O.;Liepa, A.M.;Wijayawardana, S.;Russo, F.;Walgren, R.A.;Zimmermann, A.H.;Hozak, R.R.;Bell-McGuinn, K.M.;Powles, T.;Wong, S.-L.S.;Tan, Tan T.H.;Hovey, E.J.;Clay, T.D.;Wan, Ng S.S.;Rutten, A.;Machiels, J.-P.;Dumez, H.;Cheng, S.Y.-S.;Ferrario, C.;Sengeloev, L.;Jensen, N.V.;Thibault, C.;Laguerre, B.;Joly, F.;Culine, S.;Becht, C.;Niegisch, G.;St�ckle, M.;Grimm, M.-O.;Schwentner, C.A.;Schultze-Seemann, W.;Kalofonos, H.;Mavroudis, D.;Papandreou, C.;Karavasilis, V.;R�v�sz, J.;Rosenbaum, E.;Leibowitz-Amit, R.;Kejzman, D.;Sarid, D.;Scagliotti, G.V.;Bracarda, S.;Massari, F.;Osawa, T.;Miyajima, N.;Shinohara, N.;Fukuta, Fukuta F.;Ohyama, C.;Obara, W.;Yamashita, S.;Tomita, Y.;Kawai, Kawai K.;Fukasawa, S.;Oyama, M.;Yonese, J.;Nagata, M.;Uemura, M.;Nishimura, K.;Kawakita, M.;Tsunemori, H.;Hashine, K.;Inokuchi, J.;Yokomizo, A.;Nagamori, S.;Lee, H.J.;Park, S.H.;Rha, S.Y.;Kim, Y.J.;Lee, Y.-G.;Vazquez, Cort�s L.;Lorena, Urzua Flores C.;Blaisse, R.J.B.;Erdkamp, F.L.G.;Aarts, M.J.B.;Wojcik-Tomaszewska, J.;Tomczak, P.;Sikora-Kupis, B.;Schenker, M.;Herzal, A.A.;Udrea, A.A.;Karlov, P.;Fomkin, R.;Gajate, Borau P.;Grande, E.;Delgado, Mignorance J.I.;Su, Y.-L.;Li, J.-R.;Lin, C.-L.;Lin, C.-C.;Yeh, S.-P.;Erman, M.;Urun, Y.;Golovko, Y.;Bondarenko, I.;Sinielnikov, I.;Crabb, S.J.;Syndikus, I.;Huddart, R.;Sundar, Sundar S.;Chowdhury, S.;Sarwar, N.;Flaig, T.W.;Pan, C.X.;Schwarz, J.K.;Cultrera, J.L.;Acs, P.I.;Hainsworth, J.D.;Herms, B.T.;Lawler, W.E.;Lowe, T.E. |
| 國立成功大學 |
2020-01 |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
蘇文彬; Su, Wen-Pin; Petrylak, Daniel P;deWit, Ronald;Chi, Kim N;Drakaki, Alexandra;Sternberg, Cora N;Nishiyama, Hiroyuki;Castellano, Daniel'Hussain, Syed A;Flechon, Aude;Bamias, Aristotelis;Yu, Evan Y;van der Heijden, Michiels S… etc. |
| 臺大學術典藏 |
2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa K.;Garon E.B.;Seto T.;Nishio M.;Ponce Aix S.;Paz-Ares L.;Chiu C.-H.;Park K.;Novello S.;Nadal E.;Imamura F.;Yoh K.;Jin-Yuan Shih;Au K.H.;Moro-Sibilot D.;Enatsu S.;Zimmermann A.;Frimodt-Moller B.;Visseren-Grul C.;Reck M.;Chu Q.;Cortot A.;Pujol J.-L.;Fabre E.;Lamour C.;Bischoff H.;Kollmeier J.;Kimmich M.;Engel-Riedel W.;Hammerschmidt S.;Sch?Tte W.;Syrigos K.;Ho J.C.M.;Au K.-H.;Ardizzoni A.;Pasello G.;Gregorc V.;Del Conte A.;Galetta D.;Takahashi T.;Kumagai T.;Hotta K.;Goto Y.;Hosomi Y.;Sakai H.;Takiguchi Y.;Kim Y.H.;Kurata T.;Yamaguchi H.;Daga H.;Okamoto I.;Satouchi M.;Ikeda S.;Kasahara K.;Atagi S.;Azuma K.;Aoe K.;Horio Y.;Yamamoto N.;Tanaka H.;Watanabe S.;Nogami N.;Ozaki T.;Koyama R.;Hirashima T.;Kaneda H.;Tomii K.;Fujita Y.;Seike M.;Nishimura N.;Kato T.;Ichiki M.;Saka H.;Hirano K.;Nakahara Y.;Sugawara S.;Kim S.-W.;Min Y.J.;Lee H.W.;Kang J.-H.;An H.J.;Lee K.H.;Kim J.-S.;Lee G.-W.;Lee S.Y.;Alexandru A.;Udrea A.A.;Juan-Vidal ?.;Nadal-Alforja E.;Gil-Bazo I.;Ponce-Aix S.;Rubio-Viqueira B.;Alonso Garcia M.;Felip Font E.;Fuentes Pradera J.;Coves Sarto J.;Lin M.-C.;Su W.-C.;Hsia T.-C.;Chang G.-C.;Wei Y.-F.;Su J.;Cicin I.;Goksel T.;Harputluoglu H.;Ozyilkan O.;Henning I.;Popat S.;Hatcher O.;Mileham K.;Acoba J.;Garon E.;Jung G.;Raj M.;Martin W.;Dakhil S.; Hirano K.; Nakahara Y.; Saka H.; Ichiki M.; Kato T.; Nishimura N.; Seike M.; Fujita Y.; Tomii K.; Kaneda H.; Hirashima T.; Koyama R.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Azuma K.; Atagi S.; Sch?tte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Wei Y.-F.; Chang G.-C.; Hsia T.-C.; Su W.-C.; Lin M.-C.; Coves Sarto J.; Fuentes Pradera J.; Felip Font E.; Alonso Garcia M.; Rubio-Viqueira B.; Ponce-Aix S.; Gil-Bazo I.; Nadal-Alforja E.; Juan-Vidal ?.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. |
| 臺大學術典藏 |
2022-04-14T23:27:36Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
YI-HSIN LIANG; JIN-TUNG LIANG; Lin, Ben Ren; TAI-CHUNG HUANG; JI-SHIANG HUNG; Lai, Shuo Lun; Chen, Tzu Chun; JIA-HUEI TSAI; Cheng, Yung Ming; Tsao, Ting Han; Hsu, Wen Ling; Chen, Kuo Hsing; KUN-HUEI YEH |
| 臺大學術典藏 |
2022-04-20T03:25:50Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; JIN-TUNG LIANG; Lin, Ben-Ren; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; Tsai, Jia-Huei; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-04-20T05:36:35Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; Liang, Jin-Tung; BEEN-REN LIN; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; Tsai, Jia-Huei; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-04-21T02:21:53Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; Liang, Jin-Tung; Lin, Ben-Ren; TAI-CHUNG HUANG; JI-SHIANG HUNG; Lai, Shuo-Lun; Chen, Tzu-Chun; Tsai, Jia-Huei; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-07-11T08:13:48Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; Liang, Jin-Tung; Lin, Ben-Ren; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; Tsai, Jia-Huei; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; KUO-HSING CHEN; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-07-26T08:38:07Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; Liang, Jin-Tung; Lin, Ben-Ren; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; JIA-HUEI TSAI; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-08-12T02:50:36Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang Y.-H.; Liang J.-T.; Lin B.-R.; Huang J.; Hung J.-S.; Lai S.-L.; Chen T.-C.; Tsai J.-H.; Cheng Y.-M.; Tsao T.-H.; Hsu W.-L.; Chen K.-H.; KUN-HUEI YEH |
| 臺大學術典藏 |
2019-03-04T08:08:05Z |
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
|
Cheng, Rebecca;Chung, Hyun Cheol;Orlando, Mauro;Mi, Gu;Binder, Polina;Zhang, Yawei;Sohn, JooHyuk;Yamazaki, Kentaro;Kim, Sang-We;Chao, Yee;Lee, Keun-Wook;Kudo, Masatoshi;Kim, Tae-Won;Muro, Kei;Yen, Chia-Jui;JIN-YUAN SHIH; Yen, Chia-Jui; Muro, Kei; Kim, Tae-Won; Kudo, Masatoshi; JIN-YUAN SHIH; Lee, Keun-Wook; Chao, Yee; Kim, Sang-We; Yamazaki, Kentaro; Sohn, JooHyuk; Cheng, Rebecca; Zhang, Yawei; Binder, Polina; Mi, Gu; Orlando, Mauro; Chung, Hyun Cheol |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國家衛生研究院 |
2013-11-06 |
Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma
|
Chang, KC;Chang, WC;Chang, Y;Hung, LY;Lai, CH;Yeh, YM;Chou, YW;Chen, CH |
| 國立成功大學 |
2013-11-06 |
Ran GTPase-Activating Protein 1 Is a Therapeutic Target in Diffuse Large B-Cell Lymphoma
|
Chang, Kung-Chao; Chang, Wei-Chao; Chang, Yao; Hung, Liang-Yi; Lai, Chien-Hsien; Yeh, Yu-Min; Chou, Yu-Wei; Chen, Chung-Hsuan |
Showing items 707776-707800 of 2348439 (93938 Page(s) Totally)
<< < 28307 28308 28309 28310 28311 28312 28313 28314 28315 28316 > >>
View [10|25|50] records per page
|
